Asia Pacific Firms Use Google Cloud to Modernize, Innovate
Companies in Asia Pacific need to move data and workloads from legacy systems to modern, scalable platforms for future agility. Many are turning to Google and its provider partners for the tools and services they need for that transition.
The 2025 ISG Provider Lens ® Google Cloud Partner Ecosystem report for Asia Pacific finds that companies in the region are transforming their digital infrastructures through cloud migration and data innovation. While keeping up with rapidly evolving technologies, enterprises in Asia Pacific are also under growing pressure to control costs, making it imperative that they maximize their return on cloud investments. Google Cloud's focus on addressing these challenges positions it as a preferred partner in the region.
'Companies in Asia Pacific need to move data and workloads from legacy systems to modern, scalable platforms for future agility,' said Michael Gale, partner and regional leader, ISG Asia Pacific. 'Many are turning to Google and its provider partners for the tools and services they need for that transition.'
Demand for cloud services is rising quickly in Asia Pacific, accelerated by the need for better flexibility and operational performance, the report says. Companies need effective, reliable cloud solutions to support a growing number of applications, including business intelligence and customer relationship management. Cloud adoption varies widely with differing levels of digital maturity in the region. Established markets such as Australia and New Zealand lead in advanced cloud solutions, while companies in emerging markets are rapidly integrating cloud services. In Southeast Asia, some governments are encouraging the trend with initiatives to promote digital economies.
Generative AI is also gaining traction among enterprises in the region as companies begin to see it as essential for improved operational efficiency and customer engagement, ISG says. Enterprises are exploring GenAI applications including chatbots, predictive analytics and workflow automation. Google Cloud's AI and ML tools, such as Vertex AI, are becoming integral to these efforts. The rise of AI in Asia Pacific is also increasing demand for managed services to deploy and run AI solutions.
Many enterprises in Asia Pacific are adopting hybrid cloud and multicloud strategies to balance flexibility, scalability and control by combining on-premises and public cloud resources, the report says. They are turning to service providers offering comprehensive support for these strategies, including tools such as Google Anthos for workload management across clouds.
The rising importance of advanced analytics and data visualization in the region also is driving adoption of Google Cloud solutions, ISG says. Companies are seeking real-time analytics backed by a focus on data quality and governance.
'Enterprises in Asia Pacific are recognizing that their data needs to be accurate, accessible and compliant with data protection laws,' said Sonam Chawla, lead analyst, ISG Provider Lens Research, and lead author of the report. 'Solutions that support these strategic objectives help to create trust among companies and their partners.'
The report also examines other trends in the Asia Pacific Google Cloud ecosystem, including growing demand for AI-enabled supply chain management and the rising need for data localization and security to comply with national laws.
For more insights into Google Cloud-related challenges facing enterprises in Asia Pacific, plus ISG's advice for addressing them, see the ISG Provider Lens ® Focal Points briefing here.
The 2025 ISG Provider Lens ® Google Cloud Partner Ecosystem report for Asia Pacific evaluates the capabilities of 32 providers across four quadrants: Google Cloud Professional Services (Consulting and Migration), Google Cloud Managed Services, Google Cloud Enterprise Data Infrastructure Services and Google Cloud GenAI and AI Services.
The report names Accenture, Capgemini, Cognizant, HCLTech, Infosys, Persistent Systems, TCS and Wipro as Leaders in all four quadrants. It names Tech Mahindra as a Leader in two quadrants and DXC Technology, LTIMindtree, Mantel Group and Quantiphi as Leaders in one quadrant each.
In addition, NTT DATA is named as a Rising Stars — a company with a 'promising portfolio' and 'high future potential' by ISG's definition — in two quadrants. Cloud4C and Searce are named as Rising Stars in one quadrant each.
In the area of customer experience, Persistent Systems is named the global ISG CX Star Performer for 2025 among Google Cloud Partners Ecosystem providers. Persistent Systems earned the highest customer satisfaction scores in ISG's Voice of the Customer survey, part of the ISG Star of Excellence™ program, the premier quality recognition for the technology and business services industry.
The 2025 ISG Provider Lens ® Google Cloud Partner Ecosystem report for Asia Pacific is available to subscribers or for one-time purchase on this webpage.
About ISG Provider Lens ® Research
The ISG Provider Lens ® Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage.
About ISG
ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 minutes ago
- Business Wire
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology
LYON, France--(BUSINESS WIRE)--Regulatory News: We are grateful for the confidence shown in MaaT Pharma and the support from the EIB, which is a further foundation towards the next phase of MaaT Pharma's growth on bringing the potential first microbiome-based therapy to market in Europe. MaaT Pharma (EURONEXT: MAAT – the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that it has secured a €37.5 million, 4-tranche financing from the European Investment Bank (EIB). The financing will support the advancement of its late-stage hemato-oncology clinical programs including the lead-asset Xervyteg ®, recently partnered with Clinigen in Europe, and currently under regulatory review by the European Medicines Agency (EMA) for the treatment of acute Graft-versus-Host Disease (aGvHD) and the second drug candidate, MaaT033, currently being evaluated in a Phase 2b randomized controlled trial in improving survival for patients receiving allogeneic stem cell transplants. With robust cGMP manufacturing, proprietary therapies, and a development platform, MaaT Pharma is a global leader in microbiome-based oncology, pioneering full-ecosystem therapies to improve survival in oncology. Since completing enrollment in the ARES trial for Xervyteg ® (MaaT013) in October 2024, MaaT Pharma has steadily advanced its roadmap, reporting topline results in January 2025, submitting the Marketing Authorization Application with the European Medicines Agency in June 2025, and signing an exclusive agreement for marketing and distribution in Europe with Clinigen in July 2025. The €37.5 million financing from the EIB follows a rigorous due diligence process by the EIB and further confirms MaaT Pharma's innovation, strategic vision and operational maturity. This funding is part of a global financial strategy to support the Company's development that combines various non-dilutive and dilutive sources to best preserve shareholder value. Eric Soyer, Chief Financial Officer, MaaT Pharma, said: 'We are grateful for the confidence shown in MaaT Pharma and the support from the EIB, which is a further foundation towards the next phase of MaaT Pharma's growth on bringing the potential first microbiome-based therapy to market in Europe. Each operational and financing step strengthens our track record. Following the regulatory submission to the EMA for Xervyteg ® (MaaT013) and our recent partnership with Clinigen for its commercialization, the EIB financing represents another step in reinforcing the Company's financial position. As previously announced, MaaT Pharma intends to fund its plans and development programs while preserving shareholder value in the best manner possible with a mix of non-dilutive and dilutive financial sources, and the recent announcements of both partnership financing with the Clinigen agreement and debt financing with the EIB agreement, are benchmarks to reflect that strategy.' Summary of the main terms and conditions of the Loan and Warrants The loan would be available in four (4) tranches, respectively of €3.5 million for Tranche A, €6.0 million for Tranche B, €8.0 million for Tranche C, and €20.0 million for Tranche D, each tranche with Warrants attached. Disbursement of Tranches 2 to 4 are subject to operational and financing conditions. All Tranches are redeemable after a grace period of 4 years from the date of drawing, with reimbursement over a period of 2 years (Tranche A, B and C, i.e. a maturity of 6 years) to 4 years (Tranche D, i.e. a maturity of 8 years). Each tranche will bear interests at 7%, it being provided that some interests will be deferred and paid at maturity and for Tranche C and Tranche D part of the interest will be paid quarterly. MaaT Pharma will issue warrants to the benefit of EIB at the time of (and subject to) disbursement of each tranche in a number depending, for each relevant tranche, on the amount of the relevant tranche and the average price per share paid by investors in the context of equity injection made prior to disbursement of the relevant tranche (except for tranche A where the average price per share over the last trading days preceding the date of execution of the financing agreement). Each warrant will give right to subscribe to one share at a price per warrant equal to 99% of the average price over a period of 5 trading days preceding the issuance of each Warrant. The Warrants may be exercised at any time following maturity of Tranche A. The Warrants will have a 20-year term. EIB and MaaT Pharma have also agreed on (i) a put option to the benefit of EIB under which MaaT Pharma undertook to acquire from EIB all or part of the Warrants upon occurrence of certain events and (ii) a call option to the benefit of MaaT Pharma under which EIB undertook to sell all its Warrants, upon occurrence of a public tender offer over the securities issued by MaaT Pharma. The Warrants are not transferable, except to affiliates of EIB or except in case of occurrence of certain events (including maturity date of Tranche D). In case of transfer of Warrants to third party, MaaT Pharma shall benefit from a preemptive right to acquire the Warrants first. MaaT Pharma was assisted in this transaction by Mr. Eric Briole and by Van Lanschot Kempen as Financial Advisors and McDermott Will & Emery as Legal Advisor. About EIB The European Investment Bank (EIB), whose shareholders are the Member States of the European Union (EU), is the EU's long-term financing institution. Across eight major priorities, we support investments in climate action and the environment, digital transition and technological innovation, security and defense, cohesion, agriculture and the bioeconomy, social infrastructure, capital markets union, and a stronger Europe in a more peaceful and prosperous world. In 2024, the EIB Group, which also includes the European Investment Fund (EIF), signed nearly €89 billion in new financing in support of more than 900 projects in Europe and worldwide. In France, the EIB Group signed over a hundred operations in 2024 for a total amount of €12.6 billion. Nearly 60% of the EIB Group's annual financing supports projects contributing to climate change mitigation and adaptation, as well as the creation of a healthier environment. About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as 'target,' 'believe,' 'expect,' 'aim', 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.
Business Wire
3 minutes ago
- Business Wire
Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal® in Saudi Arabia
PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth® - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, obtains marketing authorization (MA) and reimbursement status for Sibnayal® (a fixed combination of potassium citrate and potassium bicarbonate) in the Kingdom of Saudi Arabia (KSA). Marketing authorization for Sibnayal® (ADV7103) in distal Renal Tubular Acidosis (dRTA) in KSA has been granted, based on the European registration dossier. Furthermore, Saudi authorities have agreed a reimbursement rate in line with the best European pricing. This achievment results of a close collaboration between Advicenne and its local partner, Taïba Healthcare, a leading distributor of pharmaceutical products in the Gulf region. Advicenne will act as the marketing authorization holder, while Taïba Healthcare will manage local marketing activities. The incidence of dRTA is higher in Gulf countries than in Europe or the United States, and prevalence in KSA could be estimated around 600 to 800 patients. Sibnayal® is already prescribed through early access programs in several Gulf countries outside Saudi Arabia. This milestone paves the way for registrations in GCC countries where the application is filed. Didier Laurens, CEO of Advicenne, declared: 'I am particularly proud of this important achievement and wish to congratulate both Advicenne and Taïba Healthcare teams, whose efforts were instrumental in informing and convincing the Saudi health authorities. The reimbursement obtained, comparable to the highest levels recorded in Europe, further attests to the significant therapeutic value of Sibnayal® in a region with one of the highest prevalence rates of dRTA worldwide.' About Advicenne Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information, see: Disclaimer This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2024 Universal Registration Document filed with the French financial market authority on April 29, 2025 (a copy of which is available on and to the development of economic conditions, financial markets and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.
Tom's Guide
3 minutes ago
- Tom's Guide
I tested ChatGPT Agent on 5 everyday tasks — here's what happened
Since the announcement of ChatGPT Agent, I'd been eagerly awaiting the model to show up in my menu of tools. ChatGPT Plus users should all have the new model now. If you don't see it, try logging out and back in it appeared, I just had to know, could the AI actually do things like cancel subscriptions, plan a family trip and order my lunch? To find out, I tested ChatGPT Agent with five very real tasks from my everyday life. Some were impressive. Others were frustrating. But all of them offered a glimpse into what the future of AI-powered assistance might actually look like. Here's what happened when I put ChatGPT Agent to work. Prompt: 'Help me find the Big Into Energy Labubu near me.'I've already found the Big into Energy Labubu with Google Search, but I wanted to see if using ChatGPT Agent was any easier. As one of the hottest toys on the market, it's nearly impossible to track one of these things followed up questioning whether I wanted more information or to purchase one. In this case, I said purchase because information is much easier to find. From there, the AI went to work. I could actually see it checking various websites, reading information, thinking and more within the chat window. In six minutes, the Agent found the Labubu I requested, added it to the cart, and headed to the checkout. It then asked for my shipping address and credit card information. I was able to take control of ChatGPT's browser to finalize the sale. Verdict: This was much faster and easier than using Google. I will definitely be using ChatGPT Agent in the future for hard-to-find items. Prompt:"Plan a 4-day family trip to San Diego, including flights from Newark, hotel options with a pool, and activities for kids under 10. Book everything using my Google account and save an itinerary in Google Docs." When I attempted to move on to the second task, my entire computer crashed and I got an error. After logging back in again, I was able to start a new prompt was a very ambitious task, but I decided to go big to really see what the ChatGPT Agent could do. The AI truly flexed its potential and its limits with this one. The agent searched Google Flights, compared hotels with kid-friendly amenities, and listed family attractions like the San Diego Zoo, LEGOLAND, and beach days. It created a beautiful daily itinerary in Docs and even embedded links to book the trip. Luckily, booking required my manual approval. For privacy and safety reasons (thankfully), the agent doesn't auto-purchase flights or rooms. Instead, it pre-filled forms and waited for me to hit "confirm." Honestly, I don't think I could ever let AI handle this part for me. I'm too much of a control freak when it comes to vacations and I don't trust AI. Verdict: An incredible planning tool and I think it's fun to see the AI 'working' through the prompt. I don't think that will ever get old. Prompt: "Create a 5-day healthy dinner meal plan under 600 calories per meal. Then generate a grocery list, check prices at my local ShopRite, and export it to a spreadsheet." Meal planning is one of those chores that sounds easy until it's 5 p.m. and your fridge is full of random ingredients that don't go together. ChatGPT Agent solved that problem fast. It generated five balanced dinner recipes (lemon herb chicken, veggie stir-fry, ravioli, etc.) with simple ingredients and clear instructions. Then it built a grocery list categorized by section (produce, pantry, dairy), checked local prices through Instacart data, and exported everything to Google Sheets. It even told me which ingredients were on sale nearby. I emailed the list to myself to use next time I go shopping. Verdict: I often refer to AI as a 'game-changer' sometimes ad nauseum, but it's so wildly helpful for things like this, that I can't think of a better descriptor. This task felt like having a personal nutritionist and assistant rolled into one. 10/10 will use again. Prompt: "Order me a chicken Caesar wrap and a lemonade from DoorDash." Luckily, ChatGPT didn't crash after the first time and I was ready to order lunch. Immediately arriving on DoorDash, the AI asked me to log in. I wanted to make this as 'hands off' as possible so I told it to use the site as a guest. I had read in several forums that ordering food had caused some users to get frustrated at ChatGPT Agent. So I was prepared for things to go awry. The only hiccup I had was the AI not knowing my zip code because it signed in as a guest. Once I told it, everything went ordered my lunch and then handed everything over to me when it was time to pay and enter my address. Because I hadn't specified a restaurant, I was impressed by ChatGPT's ability to find a chicken Caesar wrap on its More of a helpful sidekick than a hands-free solution. This wasn't much of a time saver and I probably will order lunch for myself without using ChatGPT Agent. Prompt: 'I have to renew my license and get a real ID. Can you book an appointment for me at my local Department of Motor Vehicles?'When I got a notice in the mail the other day that I couldn't renew my license online, I got that feeling of dread in the pit of my stomach. The thought of spending hours at my local Motor Vehicle office especially in the summer, was overwhelming. But in 19 seconds, ChatGPT pulled up everything I needed to book an appointment and I was all set. Zero hassle. Verdict: Fast, smart and surprisingly effective for a niche errand. ChatGPT Agent isn't perfect, but it's one of the most capable AI tools I've tested to date. It won't replace your human assistant just yet, but if you're like me and don't have a human assistant to begin with, it's the next best thing. It can handle real, time-consuming tasks that go far beyond answering questions or summarizing PDFs. If you're already using ChatGPT Plus or Team, it's absolutely worth trying — just be prepared to step in here and there and occasionally restart the app completely. Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button.
